Eli Lilly (NYSE:LLY) announced Tuesday it expanded its weight loss drug offerings, launching new 7.5 mg and 10 mg single-dose vial formats of its popular weight loss therapy Zepbound (tirzepatide) at $499 through its direct-to-consumer website,

Lilly recently revised its revenue forecast for 2024 after seeing weaker-than-expected growth for Zepbound and diabetes brand Mounjaro in the last three months of the year, although they still showed strong growth – up 176% to $1.91 billion and 60% to $3.53 billion, respectively.

Joe Nadglowski, president and CEO of the Obesity Action (WA: ACT) Coalition (OAC), appreciated Lilly's efforts to make obesity treatment more affordable. He emphasized, however, the need for continued progress in creating a health care system offering comprehensive care, coverage, and payment for individuals with obesity, free of weight bias.

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur further demand for the medicine.

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.